From bionic eyes to cell and gene therapies in clinical therapies, it's an exciting time for emerging technologies aiming to treat blindness and the visually impaired.

ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early ...

The legal, musical, and social demise of Youtube year-end megamixes can be read as an obituary for a lost monoculture.

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Novartis AG (NYSE:NVS) Q4 2025 Earnings Call Transcript February 4, 2026 Novartis AG beats earnings expectations. Reported EPS is $2.03, expectations were $1.99. Operator: Good morning and good ...

Tons of brightness, tons of bloom.

Tucked between rolling hills and nestled along the banks of Mill Creek sits Ripley, West Virginia – a small town where your retirement dollars stretch further than your imagination and where the ...

It's thanks to these efforts that Exelixis' financial results have been solid. Revenue, earnings, and free cash flow have all ...

In fact, in the fourth quarter, 16 of our top 20 markets experienced positive year-over-year move-in rates to new customers ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and ...

While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) employ immunosuppressive regimens used in heart transplants, the precise ...

If you’re experiencing similar feelings of despair, board-certified dermatologist and skin care brand founder, Dr. Brooke ...